Olink User Group Meeting은 The Era of Next Generation Proteomics을 주제로 새롭게 출시된 Olink® Explore 3072 panels와 Olink® Signature Q100 기기를 포함한 Olink의 제품 포트폴리오가 어떻게 인간 생물학 및 약물 발견에 대한 빠른 발전을 가능하게 했는지에 대해 다룰 것입니다.
이번 UGM에 참여하여 proteomics와 multi-omics 분야 선도 과학자의 기조연설을 듣고, 복잡한 질병을 이해하기 위한 최신 연구방법 및 연구결과에 대해 해당 분야의 전문가들과 논의할 수 있는 기회를 놓치지 마세요.
Keynote Speakers
|
Combination of clinically significant proteins in plasma defines phenotype and combined biomarker associated with prognosis in critical COVID19 patients : Analysis using Olink PEA technology Hisatake Matsumoto, MD, PhD Assistant Professor, Department of Traumatology and Acute Critical Medicine @Osaka University Graduate School of Medicine, Japan |
|
Diabetes Mellitus is Associated with Accelerated Adverse Cardiac Remodeling in Patients with Hypertension: the REMODEL Study Calvin Chin, PhD Associate Professor, Senior Consultant, Clinician Scientist and the Director of the Cardiovascular Magnetic Resonance @(CMR) Center at the National Heart Centre Singapore |
|
Expanded Possibilities with Olink Explore and Signature Q100 Philippa Pettingill Director, Field Application Scientist @Olink |
|
Illumina innovations supporting multiomics research Anthony Beckhouse Sr Regional Segment Marketing Manager, Platforms, Asia Pacific and Japan @Illumina |
이번 웨비나에서는 다음과 같은 내용을 확인하실 수 있습니다.
• How an academic - pharmaceutical partnership using Olink Explore technology, UK Biobank Pharma plasma proteome initiative aims to identify ten disease specific biomarkers along with COVID specific biomarkers from 53,000 samples
• How single cell RNA-Sequencing combined with plasma proteomics gives insights into immune oncology response in the tumor microenvironment
• How Olink Explore 1536 scales to 3,000 biomarkers and Olink Target 48 and 96 offer unique benefits
• The accessibility of easy to use and sophisticated analytics to easily integrate multiomics datasets
Olink proteomics는 독자적인 PEA technology와 robust genomics 분석 tool인 Next Generation System(NGS) 또는 qPCR technology를 결합하여 multiplexed immunoassay (up to 3072) data를 제공함으로써, proteome screening에서 target 발굴 및 검증에 이르기까지 효율적인 protein biomarker 발굴을 위한 다양한 솔루션을 제공합니다.